Last reviewed 2026-04-20 · How we verify

Trombarin (ETHYL BISCOUMACETATE)

Phase 2 active Small molecule

Trombarin (generic name: ETHYL BISCOUMACETATE) is a ethyl biscoumacetate drug. It is currently in Phase 2 development.

Trombarin works by inhibiting the enzyme Vitamin K epoxide reductase complex subunit 1, which is involved in the recycling of vitamin K.

Trombarin, also known as ethyl biscoumacetate, is a small molecule drug that targets Vitamin K epoxide reductase complex subunit 1. It is a member of the ethyl biscoumacetate class and its mechanism of action is not well-documented. As a result, there is limited information available on its approved indications, commercial status, and key safety considerations. Further research is needed to fully understand the properties and potential uses of Trombarin. Its development status and regulatory history are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETHYL BISCOUMACETATE
Drug class	ethyl biscoumacetate
Target	Vitamin K epoxide reductase complex subunit 1
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Think of vitamin K as a key that helps blood clot. Trombarin blocks the recycling of this key, which can help prevent excessive blood clotting. This can be beneficial for people with certain bleeding disorders or those at risk of blood clots.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Trombarin CI brief — competitive landscape report
Trombarin updates RSS · CI watch RSS

Frequently asked questions about Trombarin

What is Trombarin?

Trombarin (ETHYL BISCOUMACETATE) is a ethyl biscoumacetate drug.

How does Trombarin work?

Trombarin works by inhibiting the enzyme Vitamin K epoxide reductase complex subunit 1, which is involved in the recycling of vitamin K.

What is the generic name of Trombarin?

ETHYL BISCOUMACETATE is the generic (nonproprietary) name of Trombarin.

What drug class is Trombarin in?

Trombarin belongs to the ethyl biscoumacetate class. See all ethyl biscoumacetate drugs at /class/ethyl-biscoumacetate.

What development phase is Trombarin in?

Trombarin is in Phase 2.

What does Trombarin target?

Trombarin targets Vitamin K epoxide reductase complex subunit 1 and is a ethyl biscoumacetate.

Drug class: All ethyl biscoumacetate drugs
Target: All drugs targeting Vitamin K epoxide reductase complex subunit 1
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing